enGene Therapeutics ENGN
NASDAQ ENGN
$1.79 +0.02 (+1.41%)
As of: Aug 21, 2026 · 10:28 AM EDT

enGene Therapeutics (ENGN) Debt Ratio (2022 - 2026)

enGene Therapeutics (ENGN) posted quarterly Debt Ratio of 0.08 for Q2 2026, up 7.87% year-over-year from 0.08 in Q2 2025, and up 10.39% quarter-over-quarter from 0.07 in Q1 2026.

enGene Therapeutics (ENGN) Debt Ratio (2022 - 2026) Analysis & Trends

enGene Therapeutics (ENGN) has reported Debt Ratio for 5 consecutive years, with 0.08 the latest figure, recorded in Q2 2026.

  • In Q2 2026, Debt Ratio rose 7.87% year-over-year to 0.08; the TTM figure through Apr 2026 stood at 0.08 (up 7.87% YoY), while the FY2025 annual figure was 0.07, down 4.19% from the prior year.
  • Debt Ratio rose to 0.08 in Q2 2026 per ENGN's latest filing, from 0.07 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.4 in Q4 2022 and bottomed at 0.07 in Q4 2025.
  • Historically, Debt Ratio has averaged 0.12 across 5 years, with a median of 0.08 in 2024.
  • Annual changes were most pronounced in 2023 — Debt Ratio sank 73.74% — and 2026, when it climbed 7.87%.
  • enGene Therapeutics' Debt Ratio stood at 0.4 in 2022, then tumbled by 73.74% to 0.11 in 2023, then slumped by 31.86% to 0.07 in 2024, then declined by 4.19% to 0.07 in 2025, then climbed by 17.07% to 0.08 in 2026.
  • Business Quant data shows ENGN's Debt Ratio at 0.08 in Q2 2026, 0.07 in Q1 2026, and 0.07 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 140.52 Bn 132.67 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.54 Bn 78.55 Bn 3.93 Bn 0.05
3 Argenx Se 65.31 Bn 60.13 Bn 1.37 Bn -
4 Moderna 61.77 Bn 56.64 Bn 52.00 Mn 0.05
5 BeOne Medicines 42.26 Bn 37.16 Bn 1.53 Bn 0.12
6 Alnylam Pharmaceuticals 31.19 Bn 27.88 Bn 992.69 Mn -
7 BioNTech SE 28.71 Bn 10.31 Bn 668.28 Mn 0.03
8 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 0.26
9 Royalty Pharma 27.35 Bn 26.52 Bn - 0.47
10 enGene Therapeutics 125.50 Mn 125.50 Mn - 0.08

Historic Data

Download Data
DateValue
Apr 30, 2026 0.08
Jan 31, 2026 0.07
Oct 31, 2025 0.07
Jul 31, 2025 0.07
Apr 30, 2025 0.08
Jan 31, 2025 0.08
Oct 31, 2024 0.07
Jul 31, 2024 0.08
Apr 30, 2024 0.08
Jan 31, 2024 0.24
Oct 31, 2023 0.11
Oct 31, 2022 0.40